Efficacy and safety of pembrolizumab for older patients with chemoresistant urothelial carcinoma assessed using propensity score matching

Author:

Nishiyama Naotaka,Kobayashi Takashi,Narita Shintaro,Hidaka Yu,Ito Katsuhiro,Maruyama Satoru,Mukai Shoichiro,Tsutsumi Masakazu,Miki Jun,Okuno Tomoya,Yoshio Yuko,Matsumoto Hiroaki,Shimazui Toru,Segawa Takehiko,Karashima Takashi,Masui Kimihiko,Fukuta Fumimasa,Tashiro Kojiro,Imai Kazuto,Suekane Shigetaka,Nagasawa Seiji,Higashi Shin,Fukui Tomohiro,Kojima Takahiro,Morita Satoshi,Ogawa Osamu,Nishiyama Hiroyuki,Kitamura Hiroshi

Publisher

Elsevier BV

Subject

Geriatrics and Gerontology,Oncology

Reference19 articles.

1. How I treat bladder cancer in elderly patients;Galsky;J Geriatr Oncol.,2015

2. Cisplatin-ineligible and chemotherapy-ineligible patients should be the focus of new drug development in patients with advanced bladder cancer;Sonpavde;Clin Genitourin Cancer,2014

3. Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer;Galsky;Urol Oncol.,2014

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3